Rapid advances in genomic technologies and their increasing clinical application are driving the need for a policy on whether to recontact patients to inform them of new genetic discoveries that may have relevance to their health. Importantly, the duty to recontact is context-specific, and professionals should be offered guidance accordingly.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pyeritz, R. E. The coming explosion in genetic testing — is there a duty to recontact? N. Engl. J. Med. 365, 1367–1369 (2011).
Otten, E. et al. Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature. Genet. Med. 17, 668–678 (2015).
David, K. L. et al. Patient re-contact after revision of genomic test results: points to consider — a statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. https://doi.org/10.1038/s41436-018-0391-z (2018).
Carrieri, D. et al. Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics. Eur. J. Hum. Genet. 27, 169–182 (2019).
Wouters, R. H. P. et al. Am I my family’s keeper? Disclosure dilemmas in next-generation sequencing. Hum. Mutat. 37, 1257–1262 (2016).
Bredenoord, A. L. et al. Disclosure of individual genetic data to research participants: the debate reconsidered. Trends Genet. 27, 41–47 (2011).
Wade, C. H. & Kalfoglou, A. L. When do genetic researchers have a duty to recontact study participants? Am. J. Bioeth. 6, 26–27 (2006).
Ploem, C. et al. A duty to recontact in the context of genetics: futuristic or realistic? Eur. J. Health Law 25, 537–553 (2018).
This paper is written as part of the technology assessment of next-generation sequencing in personalized oncology (TANGO) project, funded by ZonMw, The Hague, Netherlands.
The authors declare no competing interests.
About this article
Cite this article
Giesbertz, N.A.A., van Harten, W.H. & Bredenoord, A.L. A duty to recontact in genetics: context matters. Nat Rev Genet 20, 371–372 (2019). https://doi.org/10.1038/s41576-019-0121-7
Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications
Genome Medicine (2022)
Preferences for return of germline genome sequencing results for cancer patients and their genetic relatives in a research setting
European Journal of Human Genetics (2022)
“I wish that there was more info”: characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants
Familial Cancer (2022)
Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences
Hereditary Cancer in Clinical Practice (2021)
Human Genetics (2021)